Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Shares Purchased by Creative Financial Designs Inc. ADV

Creative Financial Designs Inc. ADV boosted its holdings in shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) by 42.7% in the 4th quarter, Holdings Channel reports. The fund owned 91,007 shares of the company’s stock after acquiring an additional 27,222 shares during the quarter. Creative Financial Designs Inc. ADV’s holdings in Actinium Pharmaceuticals were worth $115,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. XTX Topco Ltd purchased a new stake in shares of Actinium Pharmaceuticals in the third quarter valued at approximately $268,000. Wellington Management Group LLP acquired a new position in Actinium Pharmaceuticals during the third quarter worth $112,000. Los Angeles Capital Management LLC grew its holdings in Actinium Pharmaceuticals by 25.0% in the 4th quarter. Los Angeles Capital Management LLC now owns 213,950 shares of the company’s stock valued at $270,000 after buying an additional 42,770 shares in the last quarter. Barclays PLC increased its stake in shares of Actinium Pharmaceuticals by 323.0% in the 3rd quarter. Barclays PLC now owns 42,935 shares of the company’s stock worth $81,000 after acquiring an additional 32,784 shares during the last quarter. Finally, Vontobel Holding Ltd. purchased a new position in shares of Actinium Pharmaceuticals during the 4th quarter worth $32,000. Institutional investors and hedge funds own 27.50% of the company’s stock.

Actinium Pharmaceuticals Stock Up 16.5 %

ATNM stock opened at $1.41 on Friday. Actinium Pharmaceuticals, Inc. has a 52-week low of $1.03 and a 52-week high of $10.24. The stock has a market cap of $43.99 million, a price-to-earnings ratio of -1.01 and a beta of 0.10. The business has a fifty day moving average of $1.20 and a two-hundred day moving average of $1.46.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $4.00 price objective on shares of Actinium Pharmaceuticals in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $7.40.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).